Drug Trial Radar · NCT06549686
A Phase III Study of CLS2901C in Patients With Osteoarthritis of the Knee
Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
96
Planned (sponsor's estimate)
Start
Oct 20, 2023
Primary completion
Dec 31, 2028
Study completion Jul 31, 2031
Sponsor
- Lead sponsor
- CellSeed Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of CLS2901C human allogenic chondrocyte sheets used in the osteotomy + RMSC group compared to in the osteotomy alone group of patients with osteoarthritis of the knee (OAK).
Conditions
- Osteoarthritis of the Knee
Interventions
CLS2901C (human [allogeneic] chondrocyte sheets)Biological
CLS2901C (human \[allogeneic\] chondrocyte sheets)
Primary outcomes
What the sponsor says the trial is designed to measure.
- KOOS 4 score (The Knee injury and Osteoarthritis Outcome 4 score)Time frame: 52 weeks
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Ebina General Hospital/Ebina Medical Plaza
Ebina, Kanagawa, Japan · Recruiting
Tokai University Hospital
Isehara, Kanagawa, Japan · Recruiting
Yokohama Sekishinkai Hospital
Yokohama, Kanagawa, Japan · Recruiting
Yokohama City University Medical Center
Yokohama, Kanagawa, Japan · Recruiting
Yokohama Minami Kyousai Hospital
Yokohama, Kanagawa, Japan · Recruiting
Juntendo University Hospital
Bunkyō-Ku, Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.